|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
There were 14 cases (14.29%, 14/98) and 34 cases (34.70%, 34/98) of lymphomas with the DHL and DEL of MYC and BCL2/BCL6, respectively.
|
31615842 |
2020 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Following a broad panel of immunohistochemical stains, the strong positive staining of the spindle cells for LCA (CD45), CD20, and Bcl-6 confirmed the diagnosis of follicle center cell lymphoma.
|
31693188 |
2020 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
The BCL6 transcription factor plays a central role in establishing the GC phenotype in B cells, and most lymphomas are dependent on BCL6 to maintain survival, proliferation, and perhaps immune evasion.
|
30874354 |
2019 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Double/triple-hit lymphomas (DHL/THL) account for 5-10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression.
|
31288832 |
2019 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Thus BCL6 is considered to be involved in germinal center (GC)-derived lymphoma.
|
31063496 |
2019 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Aggressive lymphomas with MYC and BCL2 and/or BCL6 translocations ("double hit" lymphomas, DHL) represent a distinct diagnostic category in the updated World Health Organization (WHO) classification.
|
29629947 |
2019 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
We identified 122 patients diagnosed as having large B-cell lymphoma (44, MYC-negative; 29, MYC-EC; 23, MYC rearrangement; 22, MYC and BCL2 rearrangements; 4, MYC, BCL2, and BCL6 rearrangements). p53 expression significantly correlated with DLBCL with abnormal MYC status (MYC-EC, MYC rearrangement, and MYC overexpression), but adverse p53 prognostic effect was only seen with MYC-rearranged lymphoma.
|
30496802 |
2019 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Additionally, CD38<sup>bright</sup> may be a better indicator for predicting DH/THL-BCL2 than DHL-BCL6, and very bright CD38 expression was exclusive to MYC rearranged lymphomas.
|
30734478 |
2019 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
High grade B-cell lymphoma (HGBCL) by WHO 2016 classification requires rearrangements of MYC and BCL2 and/or BCL6, practically covering the so called "double-hit" or "triple hit" lymphomas.
|
29666005 |
2018 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Lymphomas with MYC and either BLC2 or BCL6 rearrangements or MYC and BCL-2 protein overexpression, classified as double-hit (DHL) or double-expressor (DEL) lymphomas, respectively, are associated with poorer response to standard immunochemotherapy.
|
29722657 |
2018 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Our studies identify PRMT5 as a novel regulator of the GC reaction and highlight the mechanistic rationale of cotargeting PRMT5 and BCL6 in lymphoma.
|
30082494 |
2018 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Here we show that the murine lymphoma cell line A20 resembles primary GCB cells in expression of GC-specific surface markers and the master transcription factor BCL6 and may serve as a useful system to model certain GCB cell behaviors in vitro.
|
29154209 |
2018 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Areas covered: This review examines the rationale for and challenges in therapeutic targeting of BCL6 in lymphomas.
|
29262721 |
2018 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas.
|
29785017 |
2018 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
Simple karyotyping revealed key translocations involving MYC, BCL2, and BCL6 that have impacted lymphoma classification in the World Health Organization classification scheme.
|
30213388 |
2018 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
|
29902576 |
2018 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 rearrangements, so-called "double-hit" lymphomas (HGBL-DH), are aggressive lymphomas that form a separate provisional entity in the 2016 revised World Health Organization Classification of Lymphoid Tumors.
|
27821509 |
2017 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
|
27717585 |
2017 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Therefore, identification of the normal B cell subset with the most similar gene expression pattern to a particular type of B cell lymphoma has been instrumental to deduce the precise cell of origin of lymphomas.We present here protocols to analyze human B cell lymphomas for a potential origin from GC B cells by determining the presence of mutations in rearranged IgV genes and the BCL6 gene, and by comparing the gene expression pattern of lymphoma cells with those of normal B cell subsets by genechip or RNA-sequencing analysis.
|
28589362 |
2017 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
DHL encompasses various histologies of lymphomas where the MYC oncogene and either BCL2 or BCL6 oncogenes are present concomitantly.
|
28711572 |
2017 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In this review, we summarize two sessions dedicated to "high-grade B cell lymphomas, with MYC and BCL2 and/or BCL6 rearrangements (so-called double/triple-hit lymphomas)" and "high-grade B cell lymphomas, NOS" as defined in the 2016 update of the WHO lymphoma classification, Burkitt lymphoma and related neoplasms, and terminally differentiated aggressive B cell lymphomas.
|
28844114 |
2017 |
|
Lymphoma
|
0.200 |
GeneticVariation
|
group |
BEFREE |
There were 47 DTHLs, 36 cases with MYC and BCL2 and/or BCL6 extra signals (ES) and/or rearrangements (ES group, excludes DTHLs), 9 with MYC rearrangements only (single-hit lymphoma), and 95 with no MYC abnormalities (NM).
|
28614202 |
2017 |
|
Lymphoma
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Hypermethylation of the Bcl6 locus followed by BCL6 upregulation was thought to be the key event for lymphoma development in mice.
|
27921272 |
2017 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
We demonstrate the usefulness of synthetic lethal screening of a conditionally BCL6-deficient Burkitt lymphoma cell line, DG75-AB7, with a library of small molecules to determine survival pathways suppressed by BCL6 and suggest mechanism-based treatments for lymphoma.
|
27268052 |
2016 |
|
Lymphoma
|
0.200 |
Biomarker
|
group |
BEFREE |
However BCL6 also directly represses several DLBCL oncogenes such as BCL2 and BCL-XL that promote lymphoma survival.
|
26657288 |
2016 |